Jaguar Health, Inc. (NASDAQ:JAGX)

PRESS RELEASE

published on 12/06/2023 at 14:30, 2 years 10 months ago

Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website
Napo Pharmaceuticals and Advocates for Collaborative Education (ACE) have released the abstract for a quality of life survey for individuals with a cancer diagnosis, shedding light on the challenges faced. The survey findings will be presented at the December 2023 SABCS, focusing on the impacts of cancer diagnosis and treatment on quality of life, including physical and emotional well-being, treatment side effects, and the consequences of managing those side effects

Napo Pharmaceuticals Advocates For Collaborative Education Cancer Survey Quality Of Life SABCS 2023
PRESS RELEASE

published on 12/04/2023 at 14:30, 2 years 10 months ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs
Jaguar Health, Inc. (NASDAQ:JAGX) has announced the renewal of conditional approval for Canalevia-CA1 (crofelemer delayed-release tablets) by the U.S. FDA for the treatment of chemotherapy-induced diarrhea (CID) in dogs. The renewal extends the validity until December 21, 2024, as the company plans a clinical field study to support full approval

Crofelemer FDA Approval Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea
PRESS RELEASE

published on 11/30/2023 at 14:30, 2 years 11 months ago

Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference
Jaguar Health, Inc. to present on Dec 5, 2023, at the MedInvest Oncology Investor Conference, discussing pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy

Crofelemer Jaguar Health Oncology Investor Conference Phase 3 Clinical Trial Cancer Therapy
PRESS RELEASE

published on 11/21/2023 at 14:30, 2 years 11 months ago

Top Line Data for Jaguar Health’s Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Forthcoming
PRESS RELEASE

published on 11/14/2023 at 14:00, 2 years 11 months ago

Jaguar Health Reports Third Quarter 2023 Financial Results
PRESS RELEASE

published on 11/10/2023 at 22:15, 2 years 11 months ago

Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PRESS RELEASE

published on 11/09/2023 at 14:30, 2 years 11 months ago

Breast Cancer Related Results of Groundbreaking Napo Pharmaceuticals (a Jaguar Health Family Company) Supported Study on Quality of Life for Cancer Patients and Survivors Accepted for Presentation at the December 2023 San Antonio Breast Cancer Symposium
PRESS RELEASE

published on 11/08/2023 at 16:25, 2 years 11 months ago

Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule
PRESS RELEASE

published on 11/08/2023 at 14:30, 2 years 11 months ago

Jaguar Health to Hold Investor Webcast Tuesday, November 14th at 8:30 AM Eastern Regarding Q3 2023 Financials & Corporate Updates
PRESS RELEASE

published on 11/07/2023 at 14:30, 2 years 11 months ago

REMINDER: Jaguar Health to Host Virtual Educational Webinar on Rare Intestinal Failure Diseases with Leading Gastroenterologists and Nutrition Experts November 8th from 1:00 PM to 2:30 PM EST

Published on 10/30/2026 at 23:35, 1 day 3 hours ago

Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day 4 hours ago

Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 20:47, 1 day 6 hours ago

CoTec Holdings Corp. Comments on Share Trading
Published on 10/30/2026 at 19:00, 1 day 8 hours ago

Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 1 day 12 hours ago

Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split

View all ACCESSWIRE

Published on 10/31/2026 at 16:35, 10 hours 54 minutes ago

SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 4 hours ago

EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 22:30, 1 day 4 hours ago

/C O R R E C T I O N - OCI Global/
Published on 10/30/2026 at 20:17, 1 day 7 hours ago

2CRSi SA: 2025-2026 annual results
Published on 10/30/2026 at 18:38, 1 day 8 hours ago

EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report

View all EQS

Published on 10/30/2026 at 23:00, 1 day 4 hours ago

BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 20:42, 1 day 6 hours ago

TINC and PMV invest in Storm Group (B)
Published on 10/30/2026 at 18:00, 1 day 9 hours ago

2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 1 day 15 hours ago

Capital increase through exercise of subscription rights
Published on 10/30/2026 at 08:45, 1 day 18 hours ago

Share buyback

View all LES ECHOS COMFI WIRE

News